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Objective: This randomized phase II trial compared the response rates to treatment with 
interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and 
fluorouracil alone in patients with advanced hepatocellular carcinoma. Methods: A total of 
114 patients with measurable advanced hepatocellular carcinoma were enrolled and 
randomized into 2 groups. Fluorouracil (300 mg/m
2
 days 1 – 5, days 8 – 12) with or without 
cisplatin (20 mg/m
2
, day 1, day 8) were administered via the hepatic artery. Interferon alpa-2b 
was administered 3 times per week for 4 weeks. Results: The response rates were 45.6% for 
the interferon/fluorouracil + cisplatin group and 24.6% for the interferon/fluorouracil group. 
The response rate was significantly higher in the interferon/fluorouracil + cisplatin group (p = 
0.030). The median overall survival period was 17.6 months in the interferon/fluorouracil + 
cisplatin group vs. 10.5 months in the interferon/fluorouracil group (p = 0.522). The median 
progression-free survival period was 6.5 months in the interferon/fluorouracil + cisplatin 
group vs. 3.3 months in the interferon/fluorouracil group (p = 0.0048). Hematological toxicity 
was common, but no toxicity-related deaths were observed. Conclusion: These results show 
the clinical efficacy of adding cisplatin to the hepatic arterial infusion of fluorouracil in 








Hepatocellular carcinoma (HCC) is the 6th most frequent type of cancer in the world and 
ranks third among various causes of cancer death. In recent years, the incidence of HCC has 
been increasing in Western and Asian countries [1-3]. 
 Clinical practice guidelines for HCC are currently available in Japan, and the number 
of early cases with an early single tumor with a major diameter of 2cm or less detected by 
regular screening is generally increasing[4]. The treatment of early cases, including 
hepatectomy and local therapy such as radiofrequency ablation and percutaneous ethanol 
injection therapy, has progressed markedly, achieving a 5-year survival rate of 60-70%[5]. 
Most patients with HCC often experience the repeated recurrence of tumors after treatment 
and the disease may eventually reach an advanced stage. Furthermore, it is still not 
uncommon to find patients with symptomatic advanced HCC who have not participated in 
regular screening. 
 The efficacy of hepatectomy, local ablation therapy, and transarterial 
chemoembolization (TACE) is limited for advanced HCC and the prognosis of such cases is 
poor. Under these circumstances, systemic therapy with the molecular targeting drug 
sorafenib has shown a statistically significant survival benefit, compared with placebo 
treatment, in two large-scale phase-III clinical trials [6, 7]. Based on these findings, this drug 
is now recommended as a standard treatment for advanced HCC. These trials did not compare 
sorafenib with other conventional treatments of advanced HCC, but with best supportive care 
as the placebo treatment. Although a significant difference in the survival time was noted, the 
response rate was as low as 2 – 3.3%, with no significant difference from the results in the 
placebo arm (1 – 1.3%)[6, 7].  
 As another optional treatment for advanced HCC, hepatic arterial infusion 
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chemotherapy (HAIC) has been employed mainly in Japan and other Asian countries. HAIC 
has been used for not only unresectable HCC accompanied by vascular invasion, but also 
uncontrollable cases of repeated recurrences within a short period of time despite a number of 
sessions of TACE. 
 In recent years, fluorouracil (FU) and cisplatin (CDDP) have been reported as the 
most commonly used anticancer drugs used for HAIC [8-17]. Favorable results with an HAIC 
protocol using low-dose CDDP and FU have also been reported [8, 14, 16, 17]. Similarly, 
combination of interferon (IFN) with FU has demonstrated relatively good results in HAIC 
[11, 13, 18].  
 With this background in mind and with the aim of establishing the most effective 
HAIC protocol for advanced HCC, we planned a phase-II randomized clinical comparative 
study to examine whether or not IFN combined with HAIC consisting of FU and CDDP 
might be associated with a higher response rate. Patients with advanced HCC were randomly 
allocated to two treatment arms, i.e., IFN combined with hepatic arterial infusion of FU with 
CDDP or IFN combined with hepatic arterial infusion of FU alone without CDDP. The results 




Materials and Methods 
Patients 
Patients who had histologically or clinically diagnosed HCC were included in this study. A 
clinical diagnosis of HCC was made based on underlying chronic liver disease, radiologic 
findings and elevation of tumor markers. 
 As for the tumor stage, the following patients were included: patients who had (1) 
severe vascular invasion (i.e., vascular invasion found in the main trunk to the secondary 
branches of the portal vein; or invasion in the right, middle, or left hepatic vein); (2) 
intrahepatic multiple lesions (i.e., 5 or more nodules in the left and/or right lobes as confirmed 
by radiology). 
 Patients were eligible when they were 20 years old or older, had an eastern clinical 
oncology group (ECOG) performance status of 2 or less, and had appropriate bone marrow, 
liver, kidney and cardiac functions as determined in terms of the following measurements 
obtained within 1 week before enrollment (hemoglobin, 8.0 g/dL or more; white blood cell 
count (WBC), 2,000/mm
3
 or more; platelet count, 30,000/mm
3
 or more; blood urea nitrogen 
(BUN), 30 mg/dL or less; serum creatinine, 2.0 mg/dL or less, percentage of prothrombin 
time, 30% or more; total bilirubin, 5 mg/dL or less (excluding elevations caused by biliary 
tract obstruction as a result of HCC).  
 
Assignment 
The present study was an open randomized single center study composed of a two-group 
comparison. All the patients who satisfied the inclusion criteria were randomized to either of 
the two treatments. The treatment protocol was approved by the ethical committee of 
Kanazawa University (approval number  5169). Patients were given full information 
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regarding the details of the clinical study and provided their written consent prior to 




A reservoir for hepatic arterial infusion was implanted prior to HAIC. A catheter with a side 
hole was inserted from the right femoral artery using an image-guided procedure, and the tip 
of the catheter was placed in the gastroduodenal artery or splenic artery. When more than one 
hepatic artery was present, the hepatic arteries were unified to the original proper hepatic 
artery alone. When blood flow into the gastrointestinal tract was confirmed by catheter 
angiography, the route was embolized to prevent complications. The reservoir was placed 
beneath the skin in the lower right abdomen. Medication was started at least 3 days after 
implantation. 
In the IFN/FU treatment group, patients underwent the continuous hepatic arterial infusion of 
fluorouracil (5-FU

; Kyowa Hakko, Tokyo, Japan) at a dose of 300 mg/m
2
/day for 5 days in 
the 1st and 2nd weeks (for 120 h) using an infuser pump (Baxter Infusor SV1

; Tokyo, Japan) 
in the same manner as in previous reports[18]. The maximum amount of FU infused over 5 
days was 2500 mg. IFN-2b (Intron A; Schering-Plough, Osaka, Japan) at a dose of 
3,000,000 units was intramuscularly injected 3 times a week for 4 weeks. In the IFN/FU + 
CDDP treatment group, cisplatin (Randa

; Nippon Kayaku, Tokyo, Japan) at a dose of 20 
mg/m
2
 was given by hepatic arterial infusion over 1.5 h on day 1 and day 8 prior to the 
administration of FU and after appropriate hydration and antiemetic medication. A treatment 
cycle comprised 4 weeks of drug administration including interferon administration and a 





Based on previous reports in the literature[9, 19] and the results of our studies concerning 
HAIC for the treatment of HCC using single-drug regimens, the response rate in the IFN/FU 
treatment group was assumed to be 20% and that in the IFN/FU + CDDP treatment group was 
assumed to be 50%. Based on the assumption that the ratio of the numbers of patients was 1:1, 
the  error was 0.05, the  error was 0.1, and 52 patients were necessary for each treatment 
group. Therefore, the number of patients to be included was 114, allowing a 10% dropout rate 
that would result in a total of 104 patients for the two groups. 
 
Response Assessment 
The primary endpoint was the response rate (RR), as determined using dynamic computed 
tomography (CT) or magnetic resonance imaging (MRI) performed at the end of each 
treatment cycle according to the Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.0[20].  
 Secondary endpoints were the overall survival time, progression-free survival time, 
and adverse events. The overall survival time was defined as the period from the time of 
randomization until death, and the progression-free survival time was defined as the period 
from the beginning of treatment until confirmation of progression or death. Adverse events 




The two treatment groups were compared using the Fisher direct method and the Wilcoxon 
 8 
 
rank sum test. Response factors were analyzed using logistic regression analysis. The 
cumulative survival and prognostic factors were analyzed using the Kaplan-Meier method, 






A total of 155 patients with advanced HCC were treated at our hospital between October 2003 
and September 2007. Eventually, 114 patients were allocated to the IFN/FU + CDDP 
treatment group or the IFN/FU treatment group. Three patients in the IFN/FU + CDDP group 
and two in the IFN/FU group dropped out before the end of the first cycle; therefore, a total of 
109 patients, comprising 54 patients from the former group and 55 from the latter, were 
included in the efficacy evaluation (Figure 2). 
The baseline clinical features of 114 patients are shown in Table 1. No significant 
differences in the clinical features and test results were observed between the two groups, 
with the exception of a slightly higher bilirubin level in the IFN/FU group. The patients 
classified into Barcelona Clinic Liver Cancer (BCLC) stage B had five or more nodules in the 
left and/or right lobes and were considered to be difficult to control by TACE after repeated 
TACE (68%) or multiple lesions inadequate to TACE. 
 
Response to Treatment 
Among the 57 patients in the IFN/FU + CDDP treatment group, the best study response was 
complete response (CR) in 1 (1.7%); partial response (PR) was observed in 25 (43.9%) 
patients, stable disease (SD) was observed in 15 (26.3%), and progressive disease (PD) was 
observed in 13 (22.8%). Among the 57 patients in the IFN/FU treatment group, the response 
was CR in 3 (5.3%), PR in 11 (19.3%), SD in 19 (33.3%), and PD in 22 (38.6%). The 
response rate (RR; CR + PR) was 45.6% in the IFN/FU + CDDP group and 24.6% in the 
IFN/FU group; the figure was significantly higher in the former group (p = 0.030) (Table 2). 
 Factor improved the response to treatment as indicated by a multivariate analysis was 
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only the addition of CDDP to the treatment (odds ratio [OR] 2.5 [95%CI: 1.1-6.0] (Table 3). 
 
Safety 
Table 4 shows the major adverse events. Grade 3 or 4 adverse events were found in 75 
(65.8%) of the 114 patients. Bone marrow suppression of any grade was found in 65-90% of 
the patients. Leucopenia and neutropenia were noted in about 70% of the patients, and no 
significant difference was found between the IFN/FU + CDDP group and the IFN/FU group. 
An overall reduction in hemoglobin was observed more frequently in the IFN/FU + CDDP 
group than in the IFN/FU group (91.2% vs. 75.4%, p = 0.021), although the difference was 
not significant for hemoglobin reductions of grade 3 or 4. No significant difference in the all 
grade thrombocytopenia was observed between the two groups, but thrombocytopenia of 
grade 3 or 4 were significantly more frequently in the IFN/FU + CDDP group (45.6% vs. 
22.8%, p = 0.017). However, no serious complications secondary to a reduction in platelets 
occurred. 
 Non-hematologic toxicities including general malaise, nausea, vomiting, stomatitis, 
and an elevation in serum creatinine were significantly more common in the IFN/FU + CDDP 
group, but no intergroup difference was found for grade 3 or grade 4 toxicities. 
 Peptic ulcer arising from the leakage of arterially infused anticancer drugs into the 
gastrointestinal tract, a complication characteristic of HAIC, was found in 6 (10.5%) patients 
in the IFN/FU + CDDP group and 1 (1.8%) patient in the IFN/FU group; the incidence was 
higher, but not significantly, in the IFN/FU + CDDP group (p = 0.06), and no grade 3 or grade 





The median overall survival period of the 114 patients who underwent HAIC was 12.0 
months (95% confidence interval [CI]: 11.6 – 12.4 months). In the IFN/FU + CDDP group, 
the median survival time (MST) was 17.6 months (95% CI: 9.9 – 25.3 months). On the other 
hand, in the IFN/FU group, the median survival time was 10.5 months (95%CI: 5.6 – 15.4 
months). Although the survival period tended to be higher in the group given combined 
CDDP, no statistically significant differences were observed between the two groups (p = 
0.522, log-rank test, hazard ratio [HR] 0.88 [95%CI: 0.60-1.30]) (Figure 3A).  
In the subgroup with presence of major vascular invasion, the MST was 5.8 months 
(95% CI: 3.3 – 8.3 months) in the IFN/FU + CDDP group, 4.7 months (95% CI: -7.6 – 31.6 
months) in the IFN/FU group. On the other hand, in the subgroup with absence of major 
vascular invasion, the MST was 20.0 months (95% CI: 13.6 – 26.6 months) in the IFN/FU + 
CDDP group, 12.0 months (95% CI: 4.4 – 19.6 months) in the IFN/FU group. Subanalysis 
according to presence or absence of major vascular invasion showed no significant difference 
among the two treatment groups (p = 0.571, in presence of major vascular invasion, p = 0.399 
in absence). In the subgroup with tumor stage, the MST was 22.6 months (95% CI: 0.4 – 44.7 
months) in the IFN/FU + CDDP group, 12.0 months (95% CI: 5.5 – 18.5 months) in the 
IFN/FU group. On the other hand, in the subgroup with stage IVA and stage IVB, the MST 
was 7.5 months (95% CI: 5.7 – 9.3 months) in the IFN/FU + CDDP group, 7.5 months (95% 
CI: 0.4 – 14.5 months) in the IFN/FU group. Subanalysis according to tumor stage (stage II 
and III or stage IVA and IVB) also showed no difference among two treatment groups (p = 
0.625 in stage II and III, p = 0.906 in stage IVA and IVB). 
 Similarly, the median overall progression-free survival period of the 114 patients was 
4.5 months (95%CI: 3.5 – 5.5 months). In the IFN/FU + CDDP group, the median 
progression-free survival time was 6.5 months (95%CI: 2.6 – 10.4 months). On the other hand, 
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in the IFN/FU group, the median progression-free survival time was 3.3 months (95%CI: -0.6 
– 7.2 months). The progression-free survival period was significantly longer in the IFN/FU + 
CDDP group than in the IFN/FU group (p = 0.0048, long-rank test, HR 0.57 [95%CI: 
0.38-0.85) (Figure 3B). 
 As predictors for survival, a multivariate analysis showed that positivity for hepatitis 
C virus antibody (HCV-Ab), an albumin level of 3.5 g/dL or more, and an asparate amino 





The present study showed that the addition of CDDP to IFN combined with HAIC using FU 
significantly enhanced the antitumor effect from 24.6% to 45.6%. The response rates, 
obtained in previous studies of HAIC involving at least 30 patients, varied from 14 to 71% 
[8-17]. Regarding the use of IFN combined with HAIC using FU, Obi et al. used this 
treatment in patients with advanced HCC and a tumor embolus in the main trunk or the first 
branch of the portal vein and achieved a response rate of 52.6% [13]. Ota et al. also used IFN 
combined with HAIC using FU for similar cases of advanced HCC and reported a response 
rate of 43.6% [18]. We have previously reported a response rate of 45% in 34 patients who 
underwent multidrug HAIC using FU and CDDP in combination with IFN treatment [11]. 
Uka et al. used IFN in combination with HAIC using FU in 55 patients who had a tumor 
embolus of the portal vein and reported a response rate of 29% [21]. The response rates 
obtained in the present study were similar to that obtained in the report by Uka et al. and 
lower than those obtained in the two other reports. This discrepancy may be explained by the 
different criteria used to evaluate antitumor efficacy, as Uka et al. suggested in their 
discussion. Obi et al. and Ota et al. used the ECOG criteria, whereas Uka et al. and the present 
study used the RECIST criteria. 
 The combined use of FU and IFN is reportedly beneficial because IFN serves as a 
modulator to enhance the antitumor effect of FU. More specifically, IFN induces p53, which 
enhances apoptosis by FU, and influences the cell cycle via p27
Kip1
 or apoptosis via Bcl-xL 
[22, 23]. From a clinical aspect, Takaki-Hamade et al and Eun et al concluded that combined 
IFN treatment did not have an incremental effect [24, 25]. Thus, the benefit of adding IFN to 
HAIC with FU has not been proven clinically. However, experimental data suggest that IFN 
should enhance the antitumor effect of FU [22] [26], and this supports the current use of 
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IFN-combined HAIC in clinical practice. 
 On the other hand, regarding the effect of CDDP combined with FU in a clinical 
setting, Ando et al. used HAIC with FU combined with low-dose CDDP for the treatment of 
patients with advanced HCC and a portal tumor embolus and reported a response rate of 
48%[8]. After their report, several other reports on HAIC with FU combined with low-dose 
CDDP were made, with reported response rates ranging from 38.5 – 71%[14, 16, 17, 27]. 
Experimental studies have shown that low-dose CDDP blocks methionine transport into the 
cell causing a decrease in intracellular methionine and an increase in reduced folic acid, thus 
serving as a modulator of FU to enhance its antitumor efficacy [28]. It has also been reported 
that low-dose CDDP is involved in the inhibition of p53-mediated apoptosis and drug 
resistance [29]. The present study used two agents, IFN and CDDP, in combination with FU. 
Although IFN and CDDP seem to enhance the antitumor effect of FU through these pathways, 
a large amount of basic experimental research on FU combined with these two agents remains 
to be performed. 
 Our present study showed that the antitumor effect was significantly higher and the 
progression-free survival time was significantly longer in the IFN/FU + CDDP group. 
However, there was no statistically significant difference in the overall survival time. 
Subgroup analysis also did not show survival benefit in IFN + CDDP group. Since there were 
no limitations as to treatment after the end of the protocol treatment, 88 (77.2%) of the 114 
patients underwent some treatment subsequently, and 34 (59.6%) patients in the IFN/FU 
group received HAIC (mainly IFN/FU + CDDP) eventually. This might have had some 
effects on the results concerning overall survival. 
 The factors that improved survival in this study included positivity for HCV-Ab, an 
albumin level of 3.5 g/dL or more, and an AST value of lower than 80 IU/L. Previous reports 
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have documented the presence of response to chemotherapy, the Cancer of the Liver Italian 
Program (CLIP) score, the Okuda stage, the Child-Pugh score, and alpha-fetoprotein (AFP) as 
prognostic factors of HAIC for advanced HCC [30, 31]. Obi et al. also reported that positivity 
for HCV-Ab was a predictor of the complete response to IFN combined with HAIC using 
FU[13]. Uka et al. reported that positivity for HCV-Ab was a factor involved in the early 
antitumor effect, progression-free time, and overall survival after IFN combined with HAIC 
[21]. Thus, positivity for HCV-Ab was determined as a prognosis improved factor. A possible 
explanation for this discrepancy may be that viral differences between HBV and HCV may be 
involved in the heterogeneity or anticancer drug sensitivity of HCC, or differences in the 
cytokine patterns of HBV and HCV infections may influence the effect of IFN [32-35]. 
However, the true explanation remains unclear. In connection with an AST value of lower 
than 80 IU/L, Cheong et al. also reported that low levels of AST and alkaline phosphatase 
(ALP) were associated with long-term survival exceeding 8 months in a study examining 
chemotherapy including HAIC for the treatment of patients with advanced HCC[36]. The 
basis of their argument requires further investigation. 
 Most patients with HCC have concomitant hepatic cirrhosis and thus have 
pancytopenia. Therefore, regarding the adverse events, we expected to see enhanced blood 
toxicity when IFN and CDDP were added to FU. As a result, this study showed a significantly 
higher frequency of cytopenia in the IFN/FU + CDDP group. However, as far as severe 
hematologic toxicities of grade 3 or 4 were concerned, thrombocytopenia alone was 
significantly more frequent in the IFN/FU + CDDP group, but no complications secondary to 
thrombocytopenia occurred. Although some of non-hematologic toxicities were significantly 
more frequent in the IFN/FU + CDDP group, these adverse events were controllable. Thus, 
IFN combined with HAIC using FU and CDDP seems to be tolerable with regard to the 
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occurrence of adverse events. The frequency of grade 3 or 4 toxicity of IFN-combined HAIC 
in our study was higher than sorafenib therapy reported previously [6, 7]. We enrolled 45 
patients (39.5%) in Child-Pugh class B and pretreatment blood cell count in patients of 
Child-Pugh class B was generally lower than that in Child-Pugh class A. In addition, IFN has 
effect to decrease the blood cell count especially neutrophil and platelet. However these 
toxicity were controllable and there was no toxicity-related death. 
 In conclusion, the results of this phase II randomized clinical study on the effect of 
adding CDDP to IFN in combination with HAIC using FU for the treatment of advanced 
HCC show that the combined use of CDDP significantly increases the antitumor effect of the 
treatment and induces a significant improvement in the progression-free survival time. 
Although there was no significant difference in the overall survival time of the two treatment 
groups, the survival benefit of IFN combined with HAIC using CDDP should be examined in 
comparison with systemic therapy using sorafenib, the current standard treatment for 
advanced HCC. In this connection, a multicenter study of hepatic arterial infusion of FU 
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Table 1. Patient demographics and baseline characteristics 
 
 
         IFN/FU+CDDP  IFN/FU  p-value   
                 (n=57)   (n=57) 
 
Gender (male/female)   49/8  46/11  0.62
*
 
Age (median, range, years)  65 (40-82) 68 (40-82) 0.27
†
 
PS (ECOG) (0/1/2)   36/19/2  34/21/2  0.92
†
  
Primary or recurrence   20/37  23/34  0.70
*
 
Prior TACE (+/-)   32/25  33/24  1.00
*
 
Prior Chemotherapy (+/-)  4/53  3/54  1.00
*
 
HCV-Ab (positive/negative)  32/25  35/22  0.70
*
 
HBsAg (positive/negative)  16/41  18/39  0.83
*
 
Liver cirrhosis (+/-)   46/11  47/10  1.00
*
 
Child-Pugh class (A/B/C)  33/23/1  32/22/3  0.74
†
 
LCSGJ TNM Stage (II/III/IVA/IVB)  7/26/17/7 7/20/25/5 0.53
†
 
UICC TNM Stage (II/III/IV)  6/43/8  12/38/7  0.30
†
  
BCLC Stage (B/C/D)   33/23/1  23/31/3  0.13
†
  
Diameter of tumor (median, range, mm) 37 (10-250) 40 (11-200) 0.71
†
  
Major portal vein invasion (+/-)        12/45  19/38  0.21
*
  
Lymph node metastasis (+/-)        2/55  4/53  0.68
*
 



















  78.6 ± 18.9 74.9 ± 13.8 0.22
†
 
Platelet count (x104/μL)‡  12.3 ± 6.4 11.0 ± 5.4 0.26† 
AST (IU/L)
‡





    64.2 ± 53.6 68.5 ± 88.6 1.00
†
 
DCP (<100/100≤ mAU/mL)  33/24  37/20  0.56* 
AFP (<400/400≤ ng/mL)  24/33  28/29  0.57* 
AFP-L3 (<30/30≤ %)   22/35  27/30  0.45* 
 
PS; performance status; ECOG: Eastern Cooperative Oncology Group;  
TACE: transarterial chemoembolization; HCV-Ab: hepatitis C virus antibody 
HBsAg: hepatitis B surface antigen; LCSGJ: liver cancer study group of Japan; 
UICC: Unio Internationalis Contra Cancrum; BCLC: Barcelona Clinic Liver Cancer 
AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
DCP: des-gamma-carboxy prothrombin 
AFP: alpha-fetoprotein 
*
 Fisher’s exact test 
†Wilcoxon rank sum test 





Table 2. Comparison of best study response between treatment arms 
 
 
Best study response      IFN/FU+CDDP IFN/FU       p-value
*
 
    (n=57)   (n=57) 
 
CR, n (%)    1 (1.7)    3 (5.3)  
PR, n (%)   25 (43.9)  11 (19.3) 
SD, n (%)   15 (26.3) 19 (33.3) 
PD, n (%)   13 (22.8) 22 (38.6) 
NE, n (%)    3 (5.3)    2 (3.5)  
RR (CR+PR), n (%)  26 (45.6) 14 (24.6) 0.030 
TCR (CR+PR+SD), n (%) 41 (71.9) 33 (57.9) 0.169   
 
Abbreviations: CR, complete response; PR, partial response; SD, stable response;  
PD, progressive disease; NE, not evaluable; RR, response rate;  
TCR, tumor control rate. 
*





Table 3.  Factorial analysis of predictors for response 
 
   response rate  univariate multivariate 
   (%)  analysis analysis 




odds ratio (95%CI) 
 
IFN/FU+CDDP / IFN/FU 45.6 / 25.6 0.0302 0.0268 2.5 (1.1-6.0) 
Gender (male / female) 35.8 / 31.6  0.7979 
Age (<65/65≤years) 31.1 / 39.6 0.4318 
Primary / recurrence 32.6 / 36.6 0.6909 
Prior TACE (+/-) 35.4 / 36.7 1.00 
Prior Chemotherapy (+/-) 57.1 / 33.6 0.2382 
HCV-Ab (positive/negative) 40.3 / 27.7 0.2315 
HBsAg (positive/negative) 38.2 / 33.7 0.6722 
Liver cirrhosis (+/-) 37.6 / 23.8 0.3134 
Child-Pugh class (A / B, C) 41.5 / 26.5 0.115 
LCSGJ TNM Stage (II, III / IVA, IVB)  46.7 / 22.2 0.0102 0.2877 1.3 (0.4-4.0) 
Diameter of tumor (<50/50≤ mm) 44.0 / 17.9 0.008 0.1817 2.2 (0.7-7.0) 
Major portal vein invasion (+/-) 16.1 / 42.2  0.0143 0.1266 1.8 (0.5-6.8) 
Lymph node metastasis (+/-) 33.3 / 35.2  1.00 
Distant metastasis (+/-) 16.7 / 37.3 0.2098 
Albumin (<3.5/3.5≤ g/dL) 27.6 / 42.9  0.1165 
Total bilirubin (<1.5/1.5≤ mg/dL) 39.2 / 25.7 0.2038 
Active prothrombin (<70/70≤ %) 26.8 / 39.7  0.2203 
Platelet (<10x104/10x104≤/μL) 33.3 / 36.7  0.8444 
AST (<80/80≤ IU/L) 40.8 / 25.6 0.1096 
ALT (<80/80≤ IU/L) 33.7 / 40.0 0.6372 
DCP (<100/100≤ mAU/mL) 42.5 / 57.5  0.5511 
AFP (<400/400≤ ng/mL) 38.7 / 30.8 0.4334 
AFP-L3 (<30/30≤ %) 46.6 / 22.4  0.0094 0.2898 1.7 (0.7-4.4) 
 
TACE: transarterial chemoembolization; HCV-Ab: hepatitis C virus antibody 
HBsAg: hepatitis B surface antigen; LCSGJ: liver cancer study group of Japan 
Major portal vein invasion: tumor invasion in main trunk or 1st branches of portal vein 
AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
DCP: des-gamma-carboxy prothrombin; AFP: alpha-fetoprotein; CI: confident interval 
*
 Fisher’s exact test 




Table 4. Most common adverse events 
 
Adverse events IFN/FU+CDDP (n=57) n (%)   IFN/FU (n=57) n (%) 
 
   Any grade  CTC Grade 3-4 Any grade  CTC Grade 3-4 
 
Neutrophils  44 (77.2) 17 (29.8)  37 (64.9)  19 (33.3) 
Leukocytes  43 (75.4) 12 (21.1) 38 (66.7) 18 (31.6) 
Hemoglobin  52 (91.2)
*
 4 (7.0)  43 (75.4)
*
 2 (3.5) 
Platelets  50 (89.5) 26 (45.6)
†
 48 (84.2) 13 (22.8)
†
 
Prothrombin time 30 (52.6) 3 (5.3)  32 (56.1) 1 (1.8) 
Asthenia  34 (59.6)
*
 1 (1.8)  21 (36.8)
*
 3 (5.3) 
Fever  41 (71.9) 1 (1.8)  37 (64.9) 0 (0.0) 
Nausea  32 (56.1)
*
 10 (17.5) 22 (38.6)
*
 3 (5.3) 
Vomiting  15 (26.3)
*
 4 (7.0)  4 (7.0)
*
  1 (1.8) 
Mucositis  22 (38.6)
*
 3 (5.3)  9 (15.8)
*
 1 (1.8) 
Liver function 42 (73.7) 4 (7.0)  43 (75.4) 10 (17.5) 
Creatinine  10 (17.5)
*
 0 (0.0)  2 (3.5)
*
  0 (0.0) 
Peptic ulcer  6 (10.5)  0 (0.0)  1 (1.8)  0 (0.0) 
 
CTC: common toxicity criteria 
*
 p<0.05, Wilcoxon rank sum test 





Table 5.  Factorial analysis of predictors for survival 
 
   median survival time  univariate multivariate 
   (months)  analysis analysis 




hazard ratio (95%CI) 
 
IFN/FU+CDDP / IFN/FU 17.6 / 10.5   0.522  
Gender (male / female) 12.0 / 12.0  0.236  
Age (<65/65≤years) 9.9 / 19.5 0.115  
Primary / recurrence 7.7 / 16.5 0.394  
Prior TACE (+/-) 14.4 / 12.0 0.491  
Prior Chemotherapy (+/-) 18.6 / 12.0 0.936  
HCV-Ab (positive/negative) 19.5 / 7.6 0.0049 0.0219 0.60 (0.39-0.93) 
HBsAg (positive/negative) 7.6/ 15.4 0.1145  
Liver cirrhosis (+/-) 13.7 / 9.0 0.5063  
Child-Pugh class (A / B,C) 18.6 / 9.2 0.0636  
LCSGJ TNM Stage (II, III / IVA, IVB)  19.4 / 7.5 0.0019 0.6326 0.87 (0.49-1.54) 
Diameter of tumor (<50/50≤ mm) 19.4 / 5.8 0.0014 0.1068 0.64 (0.37-1.10) 
Major portal vein invasion (+/-) 5.1 / 18.6 0.0005 0.3203 0.73 (0.40-1.35) 
Lymph node metastasis (+/-) 4.5 / 12.0  0.0789  
Distant metastasis (+/-) 4.5 / 14.0 0.0037 0.1806 0.60 (0.29-1.27) 
Albumin (<3.5/3.5≤ g/dL) 9.3 / 16.5  0.0200 0.0017 0.50 (0.32-0.77) 
Total bilirubin (<1.5/1.5≤ mg/dL) 15.4 / 9.5 0.2774  
Active prothrombin (<70/70≤ %) 9.3 / 14.5  0.9470  
Platelet (<10x104/10x104≤/μL) 16.5 / 10.5  0.6273  
AST (<80/80≤ IU/L) 19.4 / 7.4 0.0056 0.0356 0.62 (0.39-0.97) 
ALT (<80/80≤ IU/L) 13.7 / 9.5 0.8973  
DCP (<100/100≤ mAU/mL) 20.0 / 9.4 0.2294  
AFP (<400/400≤ ng/mL) 21.5 / 6.6 0.0002 0.1588 0.69 (0.41-1.16) 
AFP-L3 (<30/30≤ %) 20.8 / 7.5  0.0002 0.0730 0.61 (0.35-1.05) 
 
 
TACE: transarterial chemoembolization; HCV-Ab: hepatitis C virus antibody;  
HBsAg: hepatitis B surface antigen 
LCSGJ: liver cancer study group of Japan 
Major portal vein invasion: tumor invasion in main trunk or 1st branches of portal vein 
AST: aspartate aminotransferase; ALT: alanine aminotransferase;  













Figure 1. Treatment protocol 
 
Figure 2. CONSORT flow diagram 
 
Figure 3. Kaplan-Meier analysis of overall survival (A) and progression-free survival (B) 
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